Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2015 1
2016 2
2018 1
2019 2
2020 4
2021 3
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Update on Hypertension Research in 2021.
Mogi M, Maruhashi T, Higashi Y, Masuda T, Nagata D, Nagai M, Bokuda K, Ichihara A, Nozato Y, Toba A, Narita K, Hoshide S, Tanaka A, Node K, Yoshida Y, Shibata H, Katsurada K, Kuwabara M, Kodama T, Shinohara K, Kario K. Mogi M, et al. Hypertens Res. 2022 Aug;45(8):1276-1297. doi: 10.1038/s41440-022-00967-4. Epub 2022 Jul 5. Hypertens Res. 2022. PMID: 35790879 Free PMC article. Review.
Annual reports on hypertension research 2020.
Mogi M, Higashi Y, Bokuda K, Ichihara A, Nagata D, Tanaka A, Node K, Nozato Y, Yamamoto K, Sugimoto K, Shibata H, Hoshide S, Nishizawa H, Kario K. Mogi M, et al. Hypertens Res. 2022 Jan;45(1):15-31. doi: 10.1038/s41440-021-00766-3. Epub 2021 Oct 15. Hypertens Res. 2022. PMID: 34650193 Review.
2023 update and perspectives.
Mogi M, Tanaka A, Node K, Tomitani N, Hoshide S, Narita K, Nozato Y, Katsurada K, Maruhashi T, Higashi Y, Matsumoto C, Bokuda K, Yoshida Y, Shibata H, Toba A, Masuda T, Nagata D, Nagai M, Shinohara K, Kitada K, Kuwabara M, Kodama T, Kario K. Mogi M, et al. Hypertens Res. 2024 Jan;47(1):6-32. doi: 10.1038/s41440-023-01398-5. Epub 2023 Sep 15. Hypertens Res. 2024. PMID: 37710033 Review.
Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type 2 diabetes and chronic kidney disease (FIVE-STAR).
Tanaka A, Shibata H, Imai T, Yoshida H, Miyazono M, Takahashi N, Fukuda D, Okada Y, Teragawa H, Suwa S, Kida K, Moroi M, Taguchi I, Toyoda S, Shimabukuro M, Tanabe K, Tanaka K, Nangaku M, Node K; FIVE-STAR trial investigators. Tanaka A, et al. Cardiovasc Diabetol. 2023 Jul 31;22(1):194. doi: 10.1186/s12933-023-01928-y. Cardiovasc Diabetol. 2023. PMID: 37525257 Free PMC article. Clinical Trial.

After obtaining informed consent, eligible participants with T2D and CKD (25 mL/min/1.73 m(2) estimated glomerular filtration ratio [eGFR] < 90 mL/min/1.73 m(2) and 30 mg/g Cr urinary albumin-to-creatinine ratio [UACR] < 3500 mg/g Cr) will be equally randomize

After obtaining informed consent, eligible participants with T2D and CKD (25 mL/min/1.73 m(2) estimated glomerular filtration ratio [ …
Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib.
Endo M, Kataoka T, Fujiwara T, Tsukushi S, Takahashi M, Kobayashi E, Yamada Y, Tanaka T, Nezu Y, Hiraga H, Wasa J, Nagano A, Nakano K, Nakayama R, Hamada T, Kawano M, Torigoe T, Sakamoto A, Asanuma K, Morii T, Machida R, Sekino Y, Fukuda H, Oda Y, Ozaki T, Tanaka K. Endo M, et al. BMC Cancer. 2023 Mar 8;23(1):219. doi: 10.1186/s12885-023-10693-w. BMC Cancer. 2023. PMID: 36890471 Free PMC article.
METHODS: The JCOG1802 study is a multicenter, selection design, randomized phase II trial comparing trabectedin (1.2 mg/m(2) intravenously, every 3 weeks), eribulin (1.4 mg/m(2) intravenously, days 1 and 8, every 3 weeks), and pazopanib (800 mg orally, every day) in …
METHODS: The JCOG1802 study is a multicenter, selection design, randomized phase II trial comparing trabectedin (1.2 mg/m(2) intraven …
Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Kasai T, Mori K, Nakamura Y, Seki N, Ichikawa Y, Saito H, Kondo T, Nishikawa K, Otsu S, Bessho A, Tanaka H, Yamaguchi H, Kaburagi T, Imai H, Mori K, Ohtake J, Okamoto H. Kasai T, et al. Cancer Med. 2023 Jul;12(14):14988-14999. doi: 10.1002/cam4.6135. Epub 2023 May 24. Cancer Med. 2023. PMID: 37226421 Free PMC article. Clinical Trial.
In patients with partial response to induction therapy, median overall survival was 23.3 months in the pemetrexed alone group and 29.6 months in the pemetrexed/bevacizumab group (log-rank p = 0.077). Pretreatment monocytic (M)-MDSC counts tended to be greater in the pemetr …
In patients with partial response to induction therapy, median overall survival was 23.3 months in the pemetrexed alone group and 29.6 month …
Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping.
Suzuki Y, Oda A, Negami J, Toyama D, Tanaka R, Ono H, Ando T, Shin T, Mimata H, Itoh H, Ohno K. Suzuki Y, et al. J Lipid Res. 2022 Mar;63(3):100184. doi: 10.1016/j.jlr.2022.100184. Epub 2022 Feb 16. J Lipid Res. 2022. PMID: 35181316 Free PMC article.
Plasma samples were prepared by saponification, two-step liquid-liquid extraction, and derivatization using picolinic acid. Intense [M+H]+ signals for 4beta-OHC and 4alpha-OHC di-picolinyl esters were monitored using electrospray ionization. ...
Plasma samples were prepared by saponification, two-step liquid-liquid extraction, and derivatization using picolinic acid. Intense [M
Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia.
Wada T, Hara A, Muso E, Maruyama S, Kato S, Furuichi K, Yoshimura K, Toyama T, Sakai N, Suzuki H, Tsukamoto T, Miyazaki M, Sato E, Abe M, Shibagaki Y, Narita I, Goto S, Sakamaki Y, Yokoyama H, Mori N, Tanaka S, Yuzawa Y, Hasegawa M, Matsubara T, Wada J, Tanabe K, Masutani K, Abe Y, Tsuruya K, Fujimoto S, Iwatsubo S, Tsuda A, Suzuki H, Kasuno K, Terada Y, Nakata T, Iino N, Sofue T, Miyata H, Nakano T, Ohtake T, Kobayashi S; LICENSE study Group. Wada T, et al. Clin Exp Nephrol. 2021 Jan;25(1):1-8. doi: 10.1007/s10157-020-01959-9. Epub 2020 Aug 28. Clin Exp Nephrol. 2021. PMID: 32857255
Prevalence of Cardiovascular Disease and Its Risk Factors in Primary Aldosteronism: A Multicenter Study in Japan.
Ohno Y, Sone M, Inagaki N, Yamasaki T, Ogawa O, Takeda Y, Kurihara I, Itoh H, Umakoshi H, Tsuiki M, Ichijo T, Katabami T, Tanaka Y, Wada N, Shibayama Y, Yoshimoto T, Ogawa Y, Kawashima J, Takahashi K, Fujita M, Watanabe M, Matsuda Y, Kobayashi H, Shibata H, Kamemura K, Otsuki M, Fujii Y, Yamamoto K, Ogo A, Okamura S, Miyauchi S, Fukuoka T, Izawa S, Yoneda T, Hashimoto S, Yanase T, Suzuki T, Kawamura T, Tabara Y, Matsuda F, Naruse M; Nagahama Study; JPAS Study Group. Ohno Y, et al. Hypertension. 2018 Mar;71(3):530-537. doi: 10.1161/HYPERTENSIONAHA.117.10263. Epub 2018 Jan 22. Hypertension. 2018. PMID: 29358460
17 results